Close

Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.

×

Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Opioid crisis sparks leadership changes at Purdue Pharma

Scuttlebutt | August 21, 2018

In an attempt to distance itself from the opioid epedemic, Purdue Pharma recently made some leadership changes to its board of directors and executive committee, as it battles hundreds of lawsuits across the United States for opioid-related deceptive sales and marketing practices that are the focus of U.S. enforcement authorities.

Purdue Pharma, maker of Oxycotin, is one of the most prominent legal targets of the opioid epidemic. So, it’s no wonder the company on July 24 named Steve Miller as chairman of the Purdue board of directors, as the company seeks to get clean. Author of the The Turnaround Kid: What I Learned Rescuing Americas Most Troubled Companies, Miller has been credited with leading many critical corporate turnarounds, including the rescue of Chrysler in 1981, helping autoparts maker Delphi through...

Buy this article for $49, or subscribe to Compliance Week for a month at $149 and get unlimited article access for 30 days.